Important Matters - Haoshi Electromechanical has delivered samples of core products such as harmonic reducers and planetary reducers to certain humanoid robot manufacturers, resulting in small batch orders [1] - Aorui De's subsidiary plans to invest approximately 145 million yuan in computing power equipment, primarily for server procurement [1] - Gree Electric is focusing on research related to aluminum-to-copper technology but currently has no plans for aluminum-to-copper applications [1] - Longfly Fiber's global optical fiber and cable industry market environment is normal, with data center-related products accounting for a small proportion of total demand [1] - Hikvision reports that the price increase of hard disks has a slight positive contribution to the company's net impact [1] - Purun Co. will consider market supply and production costs for future product price adjustments [1] - Changchun High-tech's subsidiary GS3-007a dry mixed suspension drug registration clinical trial application has been accepted [1] - Litong Electronics is still in the early discussion stage for liquid cooling product development, with no AI data center project in Malaysia [1] - Rundu Co. has uncertainty regarding the approval of its innovative drug, hydrochloride dextromethorphan injection [1] - Science plans to engage in molybdenum processing and sales, while also investing in equipment for the recovery of rhenium resources during processing [1] Capital Operations - Hongxiang Co. intends to transfer 100% equity of Nantong Hanlan to Fujian Mingao [1] - Aorui De's subsidiary plans to invest approximately 145 million yuan in computing power equipment, primarily for server procurement [1] - Jichuan Pharmaceutical's wholly-owned subsidiary has signed an exclusive commercialization cooperation agreement [1] - XGIMI Technology plans to repurchase shares worth 50 million to 100 million yuan for employee stock ownership plans or equity incentives [1][2] Performance - Shanghai Yizhong reported a net profit growth of 819.42% year-on-year for 2025, with core products included in medical insurance [2] - Lianyun Technology's net profit for 2025 is expected to grow by 20.36%, benefiting from the recovery of the storage industry and increased AI demand, with growth in PCIe 3.0/4.0 and enterprise-level SATA main control chip shipments [2] Buybacks - Lexin Technology plans to repurchase shares worth 50 million to 100 million yuan, with a repurchase price not exceeding 170.29 yuan per share for employee stock ownership or equity incentives [2] - XGIMI Technology also plans to repurchase shares worth 50 million to 100 million yuan, with a repurchase price not exceeding 159.51 yuan per share for employee stock ownership plans or equity incentives [2]

审批结论：经审查，决定予以受理 适应症：特发性身材矮小（ISS） 登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 近日，长春高新技术产业（集团）股份有限公司（以下简称"公司"）控股子公司一一长春金赛药业有限 责任公司（以下简称"金赛药业"）收到国家药品监督管理局核准签发的《受理通知书》，金赛药业GS3- 007a干混悬剂的境内生产药品注册临床试验申请获得受理，现将有关情况公告如下： 一、药品的基本情况 产品名称：GS3-007a干混悬剂 申请事项：境内生产药品注册临床试验 受理号：CXHL2600135 申请人：长春金赛药业有限责任公司 公司将积极推进上述研发项目，并严格按照有关规定及时对项目后续进展情况履行信息披露义务。 特此公告 长春高新技术产业（集团）股份有限公司 二、药品的其它情况 GS3-007a干混悬剂是金赛药业自主研发的口服小分子生长激素促分泌药物，注册分类为化药1类，拟用 于特发性身材矮小（ISS）的治疗。 ISS是常见的儿童内分泌疾病，定义为身高在同年龄、性别和种族身高参考值-2 SD（标准差 ...

Company Announcements - Litong Electronics clarifies that its liquid cooling product development is still in the early discussion stage, and it does not have specific plans for product development or production [2] - Changfei Fiber announces that the global fiber optic cable market environment is normal, and new products related to data centers account for a small proportion of total demand [2] - Rundu Co., Ltd. has a Class 1 innovative drug, but the approval for its injection product remains uncertain [3] - Aorui De plans to invest approximately 145 million yuan in purchasing computing power equipment [3] Investment & Contracts - Jichuan Pharmaceutical's wholly-owned subsidiary has signed an exclusive commercialization cooperation agreement with Beijing Puqi Pharmaceutical Technology Co., Ltd. [4] Equity Changes - Hongxiang Co. plans to transfer 100% equity of Nantong Hanlan to Fujian Mingao for a total price of 120 million yuan, which will help resolve historical debt issues [5] Share Buybacks - Lexin Technology plans to repurchase shares with a total amount between 50 million and 100 million yuan for employee stock ownership or equity incentive [6] - XGIMI Technology also plans to repurchase shares with a total amount between 50 million and 100 million yuan for employee stock ownership or equity incentive [7] Business Performance - Chip导科技 reports a revenue of 394 million yuan for 2025, with a net profit of 106 million yuan, reflecting a 4.91% decrease year-on-year [8] - Sainz plans to engage in molybdenum processing and sales, aiming to recover rhenium [9] - Shenghe Resources announces the unilateral termination of its strategic cooperation with ETM, and it will take legal measures to protect its rights [10] - Lianyun Technology reports a net profit growth of 20.36% for 2025, driven by increased demand for storage products [10] - Shanghai Yizhong reports a staggering net profit growth of 819.42% for 2025, attributed to the inclusion of its core product in the national medical insurance directory [11] Other News - Beiyinmei's controlling shareholder's restructuring plan has been approved by the creditors' meeting, which may lead to changes in shareholder equity [12] - Changchun High-tech's subsidiary has received acceptance for a clinical trial application for a new drug [13][14] - Dingxin Communications' vice president has been warned and fined for suspected short-term trading of company stock [15]

公告显示，GS3-007a干混悬剂是金赛药业自主研发的口服小分子生长激素促分泌药物，注册分类为化 药1类，拟用于特发性身材矮小（ISS）的治疗。 北京商报讯（记者 丁宁）2月2日晚间，长春高新（000661）发布公告称，公司控股子公司长春金赛药 业有限责任公司（以下简称"金赛药业"）收到国家药品监督管理局核准签发的《受理通知书》，金赛药 业GS3-007a干混悬剂的境内生产药品注册临床试验申请获得受理。 ...

Mergers and Acquisitions - Changling Hydraulic plans to acquire 12% of the company's shares at an offer price of 35.82 yuan per share [1] - Chip导科技 intends to purchase 100% equity of Jishun Technology for 403 million yuan and 17.15% equity of Shunlei Technology [2] Share Buybacks - Lexin Technology plans to repurchase shares worth between 50 million to 100 million yuan for employee stock ownership or equity incentives [3] - XGIMI Technology intends to repurchase shares worth between 50 million to 100 million yuan [3] - Lingyun Optical plans to change the purpose of 348.08 million shares for repurchase and cancel them [3] - Midea Group has spent 1.998 billion yuan to repurchase 0.35% of its shares [4] - GoerTek has spent 1.108 billion yuan to repurchase 1.14% of its shares [4] External Investments and Daily Operations - Weiyuan Co. has launched a 250,000 tons/year electrolyte solvent project [5] - Far East Co. signed contracts worth 3.075 billion yuan in January through its subsidiary [6] - Changchun Gaoxin's subsidiary GS3-007a has received approval for clinical trial application for a drug [7] - Aorui De plans to invest approximately 145 million yuan in purchasing computing power equipment to provide services to clients [7] - Electric Power Water Power intends to raise funds not exceeding 3.604 billion yuan through acquisition loans [7] - Guoneng Rixin plans to increase investment of 17.625 million yuan in controlling Sanas Zhihui to enhance new energy asset operation service capabilities [7] - Science plans to engage in molybdenum processing and sales to secure a stable resource supply for rhenium recycling [7] - Panlong Pharmaceutical has received approval for clinical trials of the drug Fluorobiphenyl Patch [8] - Hongxiang Co. plans to transfer 100% equity of Nantong Hanlan New Energy for 120 million yuan [9] - Daon Co. intends to acquire equity in a Vietnamese company for a total purchase price of approximately 15.737 million USD [10] Performance Changes - Shanghai Yizhong expects a net profit of 64.132 million yuan in 2025, a year-on-year increase of 819.42%, with its core product, injectable paclitaxel polymer micelles, included in the national medical insurance directory [11] - Lianyun Technology anticipates a 20.36% year-on-year increase in net profit in 2025, driven by growth in data storage main control chips [12]

Group 1 - Far East Holdings announced that its subsidiary won a contract order worth 3.075 billion yuan, including contracts for green building cables and smart manufacturing cables [1] - Yifan Pharmaceutical received a drug registration certificate for Vitamin K1 injection, which is used to treat vitamin K deficiency-related bleeding [2] - Guangdong Electric Power A's Maoming Bohua Power Plant's Unit 4 has successfully commenced commercial operation, with a total investment of 7.484 billion yuan and an expected annual power generation of 8.6 billion kWh [4] Group 2 - Longfly Fiber reported that the global fiber optic cable industry market environment is normal, with product price fluctuations needing comprehensive assessment [25] - Shanghai Yizhong's net profit for 2025 increased by 819.42%, with total revenue of 317 million yuan, a growth of 82.72% [22] - Guizhou Power's subsidiary received a government subsidy of 200 million yuan [8] Group 3 - Zhongxing Communications plans to invest 117 million yuan in the Jianxing Zhanlu Fund, which focuses on new information technology and advanced manufacturing [10] - Suwen Electric Power's subsidiary established a joint investment fund with a total commitment of 68.5 million yuan, with Suwen contributing 5 million yuan [26] - ST Kaiyuan announced that its stock may face delisting risk due to expected negative net assets for 2025 [27]

公告显示，GS3-007a干混悬剂是金赛药业自主研发的口服小分子生长激素促分泌药物，注册分类为化 药1类，拟用于特发性身材矮小(ISS)的治疗。 智通财经APP讯，长春高新(000661.SZ)公告，公司控股子公司长春金赛药业有限责任公司(简称"金赛药 业")收到国家药品监督管理局核准签发的《受理通知书》，金赛药业GS3-007a干混悬剂的境内生产药品 注册临床试验申请获得受理。 ...

获得受理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 近日，长春高新技术产业（集团）股份有限公司（以下简称"公司"）控股 子公司——长春金赛药业有限责任公司（以下简称"金赛药业"）收到国家药品 监督管理局核准签发的《受理通知书》，金赛药业 GS3-007a 干混悬剂的境内生 产药品注册临床试验申请获得受理，现将有关情况公告如下： 证券代码：000661 证券简称：长春高新 公告编号：2026-007 一、药品的基本情况 长春高新技术产业（集团）股份有限公司 产品名称：GS3-007a 干混悬剂 关于子公司 GS3-007a 干混悬剂境内生产药品注册临床试验申请 申请事项：境内生产药品注册临床试验 受理号：CXHL2600135 此前，GS3-007a 干混悬剂已获批用于开展因内源性生长激素缺乏所引起的儿 童生长缓慢（PGHD）的临床试验，目前临床试验正在进行中。具体内容详见公司 于 2025 年 11 月 15 日在巨潮资讯网披露的《关于子公司 GS3-007a 干混悬剂境内 生产药品临床试验申请获得批准的公告》（公告编号 2025-148）。 申请 ...

Group 1 - The company Changchun Gaoxin (000661) expects a significant decline in net profit for the fiscal year 2025, projecting a range of 150 million to 220 million yuan, representing a decrease of 91.48% to 94.19% [1] - The net profit after deducting non-recurring gains and losses is anticipated to be between 437 million and 507 million yuan, reflecting a year-on-year decline of 82.09% to 84.56% [1] - Basic earnings per share are expected to be between 0.37 yuan and 0.55 yuan, a substantial drop from 6.42 yuan per share in the same period last year [1] Group 2 - The decline in net profit is attributed to increased R&D expenses as the company focuses on traditional strengths in endocrine metabolism and women's health, as well as innovative directions related to tumors, respiratory, and immune systems [1] - The company has launched its first domestic treatment for acute gouty arthritis, the innovative biological agent Jinbeixin (Fuxin Qibai monoclonal antibody), along with several other new products, leading to increased sales expenses [1] - The company's subsidiary, Changchun Baike Biotechnology Co., Ltd., is expected to report losses for the fiscal year 2025, which will further impact the company's overall performance [1] Group 3 - Changchun Jinsai Pharmaceutical Co., Ltd., a subsidiary of the company, has authorized its wholly-owned subsidiary Shanghai Saizeng Medical Technology Co., Ltd. to enter into an exclusive licensing agreement with Yarrow Bioscience, Inc. for the GenSci098 injection project [2] - The licensing agreement's related payments will not be recognized in the current reporting period due to accounting policy requirements and actual payment timelines, thus not affecting the current period's performance [2]

Market Overview - The three major indices showed mixed performance, with the Shanghai Composite Index down 0.93% at 4079.71, the Shenzhen Component Index down 0.54% at 14128.87, and the ChiNext Index up 0.65% at 3368.14 [1] Policy and Regulatory Developments - The Central Committee of the Communist Party of China emphasized the strategic importance of advancing future industries during a collective study session led by Xi Jinping [2] - The China Securities Regulatory Commission (CSRC) is focusing on deepening capital market reforms and enhancing the adaptability of regulations, including expanding the types of strategic investors for listed companies [3][3] - The National Bureau of Statistics reported a decline in the manufacturing Purchasing Managers' Index (PMI) to 49.3%, down 0.8 percentage points from the previous month, indicating a contraction in the manufacturing sector [3] Company Announcements and Financial Performance - SpaceX is applying to launch and operate a satellite constellation of up to 1 million satellites, along with building an AI data center network in orbit [3] - Companies like Zhongji Xuchuang and Xinyi Technology are projecting significant net profit increases for 2025, with estimates of 89.50%-128.17% and 231%-249% year-on-year growth, respectively [5][5] - Several companies, including Huaneng Power and China Mobile, announced expected losses for 2025, with Huaneng Power projecting a net loss of 10 billion to 16.5 billion yuan [6][7] Market Trends and Investment Insights - Citic Securities suggests a shift from speculative investments to quality assets, indicating a potential recovery window for blue-chip stocks as the ETF redemption tide appears to be ending [12] - Huatai Securities notes that while the market may experience short-term fluctuations, the core drivers for the spring market rally remain intact, with recommendations to focus on high-quality sectors such as power equipment and semiconductor devices [13]